Compare CMU & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CMU | ICCC |
|---|---|---|
| Founded | 1987 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 91.0M | 75.8M |
| IPO Year | 1994 | 1995 |
| Metric | CMU | ICCC |
|---|---|---|
| Price | $3.42 | $9.95 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 238.6K | 21.7K |
| Earning Date | 01-01-0001 | 05-15-2026 |
| Dividend Yield | ★ 4.08% | N/A |
| EPS Growth | N/A | ★ 53.85 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $26,493,169.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $50.86 | ★ N/A |
| Revenue Growth | N/A | ★ 51.64 |
| 52 Week Low | $3.21 | $4.52 |
| 52 Week High | $3.71 | $9.08 |
| Indicator | CMU | ICCC |
|---|---|---|
| Relative Strength Index (RSI) | 23.34 | 75.82 |
| Support Level | $3.41 | $5.86 |
| Resistance Level | $3.47 | N/A |
| Average True Range (ATR) | 0.04 | 0.43 |
| MACD | -0.02 | 0.03 |
| Stochastic Oscillator | 0.00 | 83.34 |
Mfs High Yield Municipal Trust is a United States-based diversified, closed-end management investment company. Its investment objective is to seek high current income exempt from federal income tax. The fund invests a majority of its net assets, including assets attributable to preferred shares and borrowings for investment purposes, in tax-exempt bonds and tax-exempt notes. The company invest various top Healthcare companies, Airport, Universities (Secondary Schools), Universities (Dormitories), and many more, out of maximum revenue is gained from Healthcare Hospitals and Long Term Care.
ImmuCell Corp is an animal health biologics company focused on the development, manufacture, and commercialization of products intended to improve the survivability, health, and long-term performance of neonatal dairy and beef calves. Its product, First Defense, utilizes hyperimmunized bovine colostrum to provide pathogen-specific antibodies and other bioactive components. First Defense is designed to provide Immediate Immunity through orally delivered antibodies against the principal viral and bacterial causes of neonatal calf diarrhea (scours), including Escherichia coli (E.coli), bovine coronavirus, and bovine rotavirus. It has two operating segments: Scours and Mastitis. It derives the majority of the revenue from the Scours segment that consists of the First Defense product line.